



ARKANSAS
DEPARTMENT OF
**HUMAN
SERVICES**

**Division of Medical Services
Medicaid Pharmacy Program**

P.O. Box 1437, Slot S415, Little Rock, AR 72203-1437
P: 501.683.4120 F: 800-424-5851

January 21, 2026

RE: Updates for Trileptal® Suspension, Tasigna® capsule, and Novolog®

Prescribers and pharmacists,

Trileptal Suspension® (oxcarbazepine) and Tasigna® capsule (nilotinib) have been brand preferred for quite some time. **Effective 1/21/2026**, both the generic and the brand will be available for dispensing to Arkansas Medicaid beneficiaries.

Generic oxcarbazepine suspension and nilotinib capsule will require DAW code of zero (0) to process the payment at the correct generic rate. Brand Trileptal® Suspension and Tasigna® capsule will require a DAW code of nine (9) to ensure the claim is processed as a plan prefers brand (PPB) product and pays at the brand rate. **After 03/01/2026**, brand Trileptal® Suspension and Tasigna® capsule will no longer be considered the plan preferred brand products while the generic will become the preferred option. The overlap of brand and generic will allow pharmacies to exhaust the brand product inventory.

Generic Novolog® (insulin aspart) and Novolog Mix® (insulin aspart/insulin aspart protamine) have been the preferred options for Medicaid beneficiaries. The manufacturer discontinued production of the generic on 12/31/2025. **Effective 1/21/2026**, brand Novolog® (insulin aspart) in the cartridge, pen, and vial and brand Novolog Mix® (insulin aspart/insulin aspart protamine) in the pen and vial will be updated to preferred status as there are no generics in production. Preferred status on the generic products will remain for pharmacies that have generics in stock.

For any questions, contact the Prime Therapeutics Help Desk at 800-424-7895.

Sincerely,

Cynthia Neuhofer, Pharm.D.
DMS Assistant Director/Pharmacy Director